课题基金 / 基金详情

IUCRC Phase I UMN: Center for Integrated Material Science and Engineering of Pharmaceutical Products (CIMSEPP)

IUCRC Phase I UMN: Center for Integrated Material Science and Engineering of Pharmaceutical Products (CIMSEPP)
IUCRC 第一期 UMN:医药产品综合材料科学与工程中心 (CIMSEPP)
批准号:
2137264
负责人:
Changquan Sun
金额:
$59.0万
依托单位国家:
美国
项目类别:
Continuing Grant
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-01 至 2027-02-28

项目摘要

项目成果

Changquan Sun的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The pharmaceutical sector in America is a major, trillion-dollar industry, having broad impacts on the US population through benefits to their health and well-being. Despite US leadership, the industry is facing major problems, including, difficulties in developing newer molecules, high cost and lengthy time of bringing a new drug to market, lack of adequate and efficient regulatory science, consumer drug affordability, quality issues, and drug shortages. The COVID-19 pandemic has further exacerbated many of these challenges. These issues point to an acute need for innovative research and technical advances to develop high-quality drug products, achieve manufacturing efficiency, and support US-based pharmaceutical manufacturing. This IUCRC phase I project addresses such issues through establishing a joint two-university Center for Integrated Material Science and Engineering for Pharmaceutical Products (CIMSEPP), with New Jersey Institute of Technology (NJIT) as the Lead Site and University of Minnesota (UMN) as a Partner Site. Its mission is to advance and promote fundamental understanding of the material properties, drug-additive interactions at molecular and particulate level, as well as manufacturing processes, on product quality and performance, at lower cost.The CIMSEPP team will develop fundamental understanding of structure-function-performance of drug products and process engineering under three industry vetted Research Thrusts: A) Particle and Crystal Engineering, B) Model Predictive Understanding of Materials and Product Performance, and C) Bioavailability Enhancement and Stability. Research at CIMSEPP will 1) promote predictive enhancement of key properties of drugs, their engineered counterparts, and their blends for improving product quality, and 2) significantly reduce time and cost of drug product development. Key advances include, 1) identification of critical particle properties that impact fine particle behavior, 2) better understanding of their impact on cohesion and behaviors of powders, and 3) enabling accurate prediction of properties of blends as well as compacted tablets. That understanding will enable the development of mechanistic models and predictive tools required for efficient manufacturing of better products. The UMN team’s expertise in powder characterization and property enhancement through integrated crystal engineering and particle design will 1) enable the development of both highly effective and easy-to-adopt strategies to solve manufacturing problems and 2) contribute to the fundamental understanding of structure – property relationship through systematic research at length scales, ranging from molecular dimension to single crystal/particles, to powders, and to finished products.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
Effect of drug loading and relative humidity on the mechanical properties and tableting performance of Celecoxib–PVP/VA 64 amorphous solid dispersions
载药量和相对湿度对塞来昔布·PVP/VA 64无定形固体分散体机械性能和压片性能的影响
DOI: 10.1016/j.ijpharm.2023.123337
发表时间: 2023
期刊: International Journal of Pharmaceutics
影响因子: 5.8
作者: [Osei-Yeboah, Frederick, Sun, Changquan Calvin]
通讯作者: Sun, Changquan Calvin
Stress transmission coefficient is a reliable and robust parameter for quantifying powder plasticity
应力传递系数是量化粉末塑性的可靠且稳健的参数
DOI: 10.1016/j.powtec.2021.117066
发表时间: 2022
期刊: Powder Technology
影响因子: 5.2
作者: [Vreeman, Gerrit, Sun, Changquan Calvin]
通讯作者: Sun, Changquan Calvin
Air entrapment during tablet compression – Diagnosis, impact on tableting performance, and mitigation strategies
片剂压缩过程中的空气滞留 — 诊断、对压片性能的影响以及缓解策略
DOI: 10.1016/j.ijpharm.2022.121514
发表时间: 2022
期刊: International Journal of Pharmaceutics
影响因子: 5.8
作者: [Vreeman, Gerrit, Sun, Changquan Calvin]
通讯作者: Sun, Changquan Calvin
Understanding the role of magnesium stearate in lowering punch sticking propensity of drugs during compression
了解硬脂酸镁在降低压缩过程中药物冲头粘连倾向方面的作用
DOI: 10.1016/j.ijpharm.2023.123016
发表时间: 2023
期刊: International Journal of Pharmaceutics
影响因子: 5.8
作者: [Gunawardana, Chamara A., Kong, Angela, Wanapun, Debbie, Blackwood, Daniel O., Travis Powell, C., Krzyzaniak, Joseph F., Thomas, Myles C., Kresevic, John E., Sun, Changquan Calvin]
通讯作者: Sun, Changquan Calvin
10
    I-Corps: Accelerated, materials sparing powder compaction characterization for improved pharmaceutical tablet formulation design
    • 批准号:
      2341264
    • 项目类别:
      Standard Grant
    • 资助金额:
      $5.0万
    • 财政年份:
      2023
    • 负责人:
      Changquan Sun
    • 依托单位:
    Planning IUCRC at University of Minnesota-Twin Cities: Center for Integrated Material Science and Engineering for Pharmaceutical Products (CIMSEPP)
    • 批准号:
      1841363
    • 项目类别:
      Standard Grant
    • 资助金额:
      $1.5万
    • 财政年份:
      2018
    • 负责人:
      Changquan Sun
    • 依托单位:
    国内基金
    海外基金
    Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark Supercooled Phase Transition
    • 批准号:
      24ZR1429700
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      YUICHIRO NAKAI
    • 依托单位:
    ATLAS实验探测器Phase 2升级
    • 批准号:
      11961141014
    • 项目类别:
      国际(地区)合作与交流项目
    • 资助金额:
      3350万元
    • 批准年份:
      2019
    • 负责人:
      刘衍文
    • 依托单位:
    地幔含水相Phase E的温度压力稳定区域与晶体结构研究
    • 批准号:
      41802035
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      12.0万元
    • 批准年份:
      2018
    • 负责人:
      张里
    • 依托单位:
    基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究